TTP is working in partnership with Dyson on a new ventilator, CoVent, which aims to increase the number of ventilators available to the NHS. This work is part of a wider initiative that includes other, novel ventilator designs that are being pursued in parallel. These ventilators are urgently needed for treating COVID-19 patients suffering with Acute Respiratory Distress Syndrome (ARDS).
On 13th March, a group of leading medical device development companies from Cambridge was asked by the UK Government to assist in the rapid development and manufacture of ventilators to meet increased hospital requirements, caused by COVID-19.
TTP plc (TTP), a leading independent technology and product development company, has today announced it has entered into a partnership with ME SOLshare Ltd (‘SOLshare’), a social enterprise that has created a new approach to distributing and trading affordable solar electricity across peer-topeer micro-grids. By making improvements to the SOLbox trading platform, the collaboration aims to increase the supply of sustainable electrical power to communities in developing countries.
TTP plc (TTP), a leading independent technology and product development company, today announced it has established a partnership with NHS Highland and The University of the Highlands and Islands, to use clinical data interpretation and machine learning algorithms to predict which patients with atrial fibrillation (AF) are able to be successfully treated using electrical cardioversion (ECV).
TTP and DiaSorin have signed an exclusive licence and technology transfer agreement. DiaSorin will combine its extensive molecular test offering with TTP’s Puckdx™ platform to develop a single-use, sample-to-answer, molecular diagnostics point-of-care platform for human IVD applications.
TTP plc (TTP), a leading independent technology and product development company, today announced that its Desktop BiologyTM service has enabled the fast-track development of a novel technology in partnership with DnaNudge Ltd, the developer of the world’s first DNA-based service to “nudge” consumers towards genetically optimal buying behaviour. The technology is designed to help consumers make healthier food and drink choices based on their unique genetic profile.
Alexander Carr, consultant at TTP plc, contributes to the latest Biocompare Article. Super resolution microscopy (SRM) takes the resolution of optical microscopy below the diffraction limit of light.
TTP plc (TTP), a leading independent technology and product development company, has successfully demonstrated a reverse transcriptase-free RNA detection method.
TTP plc, a leading independent technology and product development company, and the Medical Research Council (MRC) will co-fund a PhD student at Imperial College London to develop new tools for production of cell therapies and cell-based products.
TTP plc (TTP), a leading independent technology and product development company, has announced today that it has partnered with Quotient Ltd to develop and implement a state-of-the-art manufacturing facility for Quotient’s proprietary MosaiQ™ system.
